Effective Date:

Monday, November 07, 2011

New Tests and Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, November 07, 2011

New Tests - Tests recently added to the NMS Labs test menu. *New Tests are effective immediately.*

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0460R	Arsenic, RBCs								•	
0638H	Beryllium, Hair								•	
0638N	Beryllium, Nails								•	
0638R	Beryllium, RBCs								•	
0638TI	Beryllium, Tissue								•	
0995U	Carbon Disulfide Exposure (TTCA), Urine		•		•				•	
1033ST	Cathartic Laxatives Profile, Stool								•	
1111U	Chlorobenzene Exposure (p-Chlorophenol), Urine		•		•				•	
1140B	Chloroquine, Blood (Forensic)				•					
1140FL	Chloroquine, Fluid				•					
1140SP	Chloroquine, Serum/Plasma				•					
1140U	Chloroquine, Urine				•					
1475U	Dechlorane, Urine									•
54112B	Drug Impaired Driving/DRE Toxicology Quetiapine Confirmation, Blood (Forensic)			•						
54112U	Drug Impaired Driving/DRE Toxicology Quetiapine Confirmation, Urine (Forensic)			•						
8755B	Hallucinogens Screen - Expanded, Blood				•					
8755SP	Hallucinogens Screen - Expanded, Serum/Plasma				•					
8755U	Hallucinogens Screen - Expanded, Urine				•					
2321FL	Hydrocarbon and Oxygenated Volatiles Panel, Fluid								•	
2321TI	Hydrocarbon and Oxygenated Volatiles Panel, Tissue								•	
2551R	Magnesium - Total, RBCs								•	
2623B	Mephedrone & MDPV Stimulants Designer Drug Test, Blood	•								
2623U	Mephedrone & MDPV Stimulants Designer Drug Test, Urine	•								
6153R	Metals Panel 1, RBCs								•	
3066R	Mineral Profile, RBCs								•	
3765ST	Phosphorus - Total, Stool								•	
52112B	Quetiapine Confirmation, Blood (Forensic)			•						
53112B	Quetiapine Confirmation, Blood (Forensic)			•						

Effective Date:

Monday, November 07, 2011

New Tests and Test Updates

Test Code	Test Name	New Test	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52112FL	Quetiapine Confirmation, Fluid (Forensic)			•						
53112FL	Quetiapine Confirmation, Fluid (Forensic)			•						
52112SP	Quetiapine Confirmation, Serum/Plasma (Forensic)			•						
53112SP	Quetiapine Confirmation, Serum/Plasma (Forensic)			•						
52112TI	Quetiapine Confirmation, Tissue (Forensic)			•						
53112TI	Quetiapine Confirmation, Tissue (Forensic)			•						
52112U	Quetiapine Confirmation, Urine (Forensic)			•						
53112U	Quetiapine Confirmation, Urine (Forensic)			•						
4355U	Tetrahydrofuran, Urine			•	•				•	

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

New Tests and Test Updates

New Tests

2623B Mephedrone & MDPV Stimulants Designer Drug Test, Blood — **Effective Immediately**

Scope of Analysis:	MDPV [LC-MS/MS], Mephedrone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Identification and quantitation in biologic matrices for Antemortem Toxicology and Postmortem Toxicology
Category:	Stimulant
Specimen Requirements:	1 mL Blood
Minimum Volume:	0.4 mL
Special Handling:	None
Specimen Container:	Lavender top tube (EDTA)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday 2nd Shift 3 days (after set-up)
CPT Code:	83789

Compound Name / Alias	Units	RL	Reference Comment
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone; Meow Meow; Sunshine; synthetic stimulant	ng/mL	20	Mephedrone is a psychoactive compound that is structurally related to amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils. In two fatalities where mephedrone intoxication was determined to be the cause of death blood concentrations were 22000 ng/mL and 3300 ng/mL.
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; Bath salts; MDPK; Magic; Mtv; Peevee; Super Coke	ng/mL	10	MDPV is a synthetic stimulant reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation. Based on an in vitro human liver microsome study, 80% of MDPV may remain unchanged in the urine, while 7% is metabolized to catechol pyrovalerone and 10% to methylcatechol pyrovalerone. Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus, and peripheral neuropathies and dizziness.

New Tests and Test Updates

New Tests

2623U **Mephedrone & MDPV Stimulants Designer Drug Test, Urine** **Effective Immediately**

Scope of Analysis:	MDPV [LC-MS/MS], Mephedrone [LC-MS/MS]
Method(s):	High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)
Purpose:	Identification and quantitation in biologic matrices for Antemortem Toxicology and Postmortem Toxicology
Category:	Stimulant
Specimen Requirements:	1 mL Urine
Minimum Volume:	0.22 mL
Special Handling:	None
Specimen Container:	Plastic container (preservative-free)
Transport Temperature:	Refrigerated
Light Protection:	Not Required
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Method: High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Set-Up Days / TAT:	Monday 2nd Shift 3 days (after set-up)
CPT Code:	83789

Compound Name / Alias	Units	RL	Reference Comment
Mephedrone 4-MMC; 4-methyl-N-methcathinone; 4-methylmethcathinone; Meow Meow; Sunshine; synthetic stimulant	ng/mL	200	Mephedrone is a psychoactive compound that is structurally related to amphetamine. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. Reported adverse effects include peripheral vasoconstriction resulting in a bruised appearance on the arms and legs, loss of appetite, poor concentration, increased heart rate, sweating with an odor, and dilation of the pupils.
MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylpentan-1-one; Bath salts; MDPK; Magic; Mtv; Peevee; Super Coke	ng/mL	100	MDPV is a synthetic stimulant reported to have effects similar to methylphenidate at low doses and cocaine at high doses. Desired outcomes following use include increased energy and sociability, increased concentration, psychedelic effects and sexual stimulation. Based on an in vitro human liver microsome study, 80% of MDPV may remain unchanged in the urine, while 7% is metabolized to catechol pyrovalerone and 10% to methylcatechol pyrovalerone. Reported adverse effects include insomnia, severe agitation/anxiety, panic attacks, kidney pain, stomach cramps, tachycardia, hypertension, dilated pupils, headache, tinnitus, and peripheral neuropathies and dizziness.

New Tests and Test Updates

Test Changes

0460R Arsenic, RBCs

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/MS (82175): Arsenic
Method (CPT Code)

Compound Name	Units	Reference Comment
Arsenic	mcg/L	Reported overnight fasting reference range: 0.47 - 22 mcg/L Mean = 4.8 mcg/L Median = 2.0 mcg/L 19 of 21 normal subjects had concentrations less than 9.5 mcg/L Not for clinical diagnostic purposes. Various states require that levels above certain cutoffs must be reported to the state in which the patient resides. Please contact NMS Labs if you need assistance in supplying your state with the required information.

0638H Beryllium, Hair

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/MS (80103, 83018): Beryllium
Method (CPT Code)

Compound Name	Units	Reference Comment
Beryllium	mcg/g	No reference data available. Not for clinical diagnostic purposes.

0638N Beryllium, Nails

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/MS (80103, 83018): Beryllium
Method (CPT Code)

Compound Name	Units	Reference Comment
Beryllium	mcg/g	No reference data available. Not for clinical diagnostic purposes.

0638R Beryllium, RBCs

New Tests and Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/MS (83018): Beryllium
Method (CPT Code)

Compound Name	Units	Reference Comment
Beryllium	mcg/L	No reference data available. Not for clinical diagnostic purposes.

0638TI Beryllium, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/MS (80103, 83018): Beryllium
Method (CPT Code)

Compound Name	Units	Reference Comment
Beryllium	mcg/g	No reference data available. Not for clinical diagnostic purposes.

0995U Carbon Disulfide Exposure (TTCA), Urine

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Reference Comment was changed.

Specimen Requirements: 5 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift.
Rejection Criteria: Received Room Temperature.
Scope of Analysis: Colorimetry (82570): Creatinine
Method (CPT Code) LC-MS/MS (83789): 2-Thiothiazolidine-4-Carboxylic Acid, 2-Thiothiazolidine-4-Carboxylic Acid (Creatinine corrected)

Compound Name	Units	Reference Comment
2-Thiothiazolidine-4-Carboxylic Acid (Creatinine corrected)	mg/g Creat	Biological Exposure Index (ACGIH): Following workplace exposure to Carbon Disulfide: 0.5 mg TTCA/g Creatinine measured in a urine specimen collected at end of shift.

1033ST Cathartic Laxatives Profile, Stool

New Tests and Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: FAAS (80103, 83735): Magnesium
Method (CPT Code) ICP/AES (80103, 84100): Phosphorus

Compound Name	Units	Reference Comment
Magnesium	mg/g	Magnesium concentrations in stool water above the normal levels of 0.7 - 1.2 mg/mL have been indicative of surreptitious abuse of magnesium containing laxatives. NMS Labs calculated normal: Approximately 0.5 - 10 mg/g. (Based on the reported range of magnesium eliminated per day in stool and the range of stool mass per day in adults). Not for clinical diagnostic purposes.
Phosphorus	mg/g	Phosphorus concentrations in stool water averaged 1.8 +/- 0.3 mg/mL (ranged from 0.3 - 4.2 mg/mL) following administration of 105 mmol of sodium phosphate. NMS Labs calculated normal: Approximately 1.4 - 22 mg/g. (Based on the reported range of phosphorus eliminated per day in stool and the range of stool mass per day in adults). Not for clinical diagnostic purposes.

1111U Chlorobenzene Exposure (p-Chlorophenol), Urine

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Reference Comment was changed.

Specimen Requirements: 6 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Collect sample at end of shift at end of work week.
Rejection Criteria: None
Scope of Analysis: Colorimetry (82570): Creatinine
Method (CPT Code) GC (84600): p-Chlorophenol, p-Chlorophenol (Creatinine corrected)

New Tests and Test Updates

Test Changes

Compound Name	Units	Reference Comment
p-Chlorophenol (Creatinine corrected)	mg/g Creat	Biological Exposure Index (ACGIH): Following workplace exposure to Chlorobenzene: 20 mg p-Chlorophenol/g Creatinine measured in a urine specimen collected at end of shift at end of work week.

1140B Chloroquine, Blood (Forensic)

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

1140FL Chloroquine, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 3 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

1140SP Chloroquine, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum is not recommended for therapeutic monitoring due to variable release of chloroquine during clotting.
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Glass container. Polymer gel separation tube (SST or PST).

New Tests and Test Updates

Test Changes

1140U Chloroquine, Urine

Summary of Changes:	Specimen Requirements were changed.
Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None

54112B Drug Impaired Driving/DRE Toxicology Quetiapine Confirmation, Blood (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Quetiapine

54112U Drug Impaired Driving/DRE Toxicology Quetiapine Confirmation, Urine (Forensic)

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Quetiapine

8755B Hallucinogens Screen - Expanded, Blood

Summary of Changes:	Specimen Requirements were changed.
Specimen Requirements:	7 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Yes
Special Handling:	Glass containers are not acceptable.
Rejection Criteria:	Not received Light Protected. Glass container.

8755SP Hallucinogens Screen - Expanded, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed.

New Tests and Test Updates

Test Changes

Specimen Requirements: 7 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Yes
Special Handling: Glass containers are not acceptable. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Not received Light Protected. Glass container. Polymer gel separation tube (SST or PST).

8755U Hallucinogens Screen - Expanded, Urine

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 6 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Yes
Special Handling: Glass containers are not acceptable.
Rejection Criteria: Not received Light Protected. Glass container.

2321FL Hydrocarbon and Oxygenated Volatiles Panel, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Headspace GC (84600): Benzene, Ethyl Benzene, Styrene, Toluene, Xylenes (o,m,p), n-Heptane, n-Hexane, Methylpentanes (2- and 3- Isomers), Pentane, n-Butanol, Ethanol, Isopropanol, n-Propanol, Methanol, Acetaldehyde, Acetone, Methyl Ethyl Ketone, Methyl Isobutyl Ketone, Methyl n-Butyl Ketone, Ethyl Acetate, Diethyl Ether, Methyl Acrylate, Methyl Tertiary Butyl Ether
Method (CPT Code)

Compound Name	Units	Reference Comment
Acetaldehyde	mg/dL	Acetaldehyde is an unstable compound post-collection. It will both form and degrade under certain conditions. Although extreme precautions have been demonstrated to maintain the integrity of Acetaldehyde, the results will be affected under typical collection and laboratory procedures.

2321TI Hydrocarbon and Oxygenated Volatiles Panel, Tissue

Summary of Changes: Reference Comment was changed.

New Tests and Test Updates

Test Changes

Scope of Analysis: Method (CPT Code): Headspace GC (80103, 84600): Benzene, Ethyl Benzene, Styrene, Toluene, Xylenes (o,m,p), n-Heptane, n-Hexane, Methylpentanes (2- and 3- Isomers), Pentane, n-Butanol, Ethanol, Isopropanol, n-Propanol, Methanol, Acetaldehyde, Acetone, Methyl Ethyl Ketone, Methyl Isobutyl Ketone, Methyl n-Butyl Ketone, Ethyl Acetate, Diethyl Ether, Methyl Acrylate, Methyl Tertiary Butyl Ether

Compound Name	Units	Reference Comment
Acetaldehyde	mg/100g	Acetaldehyde is an unstable compound post-collection. It will both form and degrade under certain conditions. Although extreme precautions have been demonstrated to maintain the integrity of Acetaldehyde, the results will be affected under typical collection and laboratory procedures.

2551R Magnesium - Total, RBCs

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): FAAS (83735): Magnesium

Compound Name	Units	Reference Comment
Magnesium	mg/dL	Normal Adults: 3.0 - 6.1 mg/dL (5th to 95th percentile). Not for clinical diagnostic purposes.

6153R Metals Panel 1, RBCs

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): ICP/MS (82495): Chromium
FAAS (84630): Zinc
FAAS (82525): Copper
FAAS (84132): Potassium
FAAS (83735): Magnesium
ICP/AES (82310): Calcium

Compound Name	Units	Reference Comment
Magnesium	mg/dL	Normal Adults: 3.0 - 6.1 mg/dL (5th to 95th percentile). Not for clinical diagnostic purposes.

3066R Mineral Profile, RBCs

Summary of Changes: Reference Comment was changed.

New Tests and Test Updates

Test Changes

Scope of Analysis: ICP/MS (84255): Selenium
Method (CPT Code) ICP/MS (83018): Molybdenum
ICP/MS (83785): Manganese
ICP/MS (83018): Cobalt, Chromium
FAAS (84630): Zinc
FAAS (82525): Copper
FAAS (83735): Magnesium

Compound Name	Units	Reference Comment
Magnesium	mg/dL	Normal Adults: 3.0 - 6.1 mg/dL (5th to 95th percentile). Not for clinical diagnostic purposes.

3765ST Phosphorus - Total, Stool

Summary of Changes: Reference Comment was changed.

Scope of Analysis: ICP/AES (84100, 80103): Phosphorus
Method (CPT Code)

Compound Name	Units	Reference Comment
Phosphorus	mg/g	Phosphorus concentrations in stool water averaged 1.8 +/- 0.3 mg/mL (ranged from 0.3 - 4.2 mg/mL) following administration of 105 mmol of sodium phosphate. NMS Labs calculated normal: Approximately 1.4 - 22 mg/g. (Based on the reported range of phosphorus eliminated per day in stool and the range of stool mass per day in adults). Not for clinical diagnostic purposes.

52112B Quetiapine Confirmation, Blood (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: LC-MS/MS (83789): Quetiapine
Method (CPT Code)

53112B Quetiapine Confirmation, Blood (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: LC-MS/MS (83789): Quetiapine
Method (CPT Code)

52112FL Quetiapine Confirmation, Fluid (Forensic)

New Tests and Test Updates

Test Changes

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Quetiapine

53112FL Quetiapine Confirmation, Fluid (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Quetiapine

52112SP Quetiapine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Quetiapine

53112SP Quetiapine Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Quetiapine

52112TI Quetiapine Confirmation, Tissue (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80103, 83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80103, 83789): Quetiapine

53112TI Quetiapine Confirmation, Tissue (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80103, 83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (80103, 83789): Quetiapine

52112U Quetiapine Confirmation, Urine (Forensic)

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (83789)]

Scope of Analysis: Method (CPT Code): LC-MS/MS (83789): Quetiapine

53112U Quetiapine Confirmation, Urine (Forensic)

New Tests and Test Updates

Test Changes

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (83789)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (83789): Quetiapine

4355U Tetrahydrofuran, Urine

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Reference Comment was changed. Methods/CPT Codes were changed [Headspace GC (82491)]

Specimen Requirements:	2 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Collect sample at end of shift.
Rejection Criteria:	Received Room Temperature.
Scope of Analysis: Method (CPT Code)	Headspace GC (82491): Tetrahydrofuran

Compound Name	Units	Reference Comment
Tetrahydrofuran	mcg/mL	Biological Exposure Index (ACGIH): Following workplace exposure to Tetrahydrofuran: 2 mcg/mL measured in a urine specimen collected at end of shift.

New Tests and Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
1475U	Dechlorane, Urine	No Alternate Tests Available